234 related articles for article (PubMed ID: 25872549)
21. Human papillomavirus and the HPV vaccine: are the benefits worth the risks?
Knudtson M; Tiso S; Phillips S
Nurs Clin North Am; 2009 Sep; 44(3):293-9. PubMed ID: 19683091
[TBL] [Abstract][Full Text] [Related]
22. Syncope after vaccination--United States, January 2005-July 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 May; 57(17):457-60. PubMed ID: 18451756
[TBL] [Abstract][Full Text] [Related]
23. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
Insinga RP; Dasbach EJ; Allen SE; Carides GW; Myers ER
Value Health; 2008 Dec; 11(7):1022-32. PubMed ID: 18489503
[TBL] [Abstract][Full Text] [Related]
24. HPV vaccination - a paradigm shift in public health.
May J
Aust Fam Physician; 2007 Mar; 36(3):106-11. PubMed ID: 17339969
[TBL] [Abstract][Full Text] [Related]
25. Hospital Records of Pain, Fatigue, or Circulatory Symptoms in Girls Exposed to Human Papillomavirus Vaccination: Cohort, Self-Controlled Case Series, and Population Time Trend Studies.
Thomsen RW; Öztürk B; Pedersen L; Nicolaisen SK; Petersen I; Olsen J; Sørensen HT
Am J Epidemiol; 2020 Apr; 189(4):277-285. PubMed ID: 31899791
[TBL] [Abstract][Full Text] [Related]
26. The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
Ansstasiou-Fotaki P; Deligeoroglou E; Kreatsas G
Akush Ginekol (Sofiia); 2007; 46(3):17-20. PubMed ID: 18018777
[TBL] [Abstract][Full Text] [Related]
27. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
Pomfret TC; Gagnon JM; Gilchrist AT
J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
[TBL] [Abstract][Full Text] [Related]
28. A Blinded Comparison of Injection Pain With Quadrivalent Human Papilloma Virus Vaccine Versus Other Vaccines.
Joseph Burns J; Flock N; Lopez M; Hobby L; Lopez-Beyer A; Amin R
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):396-7. PubMed ID: 26501471
[No Abstract] [Full Text] [Related]
29. CNS demyelination and quadrivalent HPV vaccination.
Sutton I; Lahoria R; Tan I; Clouston P; Barnett M
Mult Scler; 2009 Jan; 15(1):116-9. PubMed ID: 18805844
[TBL] [Abstract][Full Text] [Related]
30. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
31. Accidental HPV vaccination in pregnancy: no adverse effects.
Balakrishnan VS
Lancet Oncol; 2017 May; 18(5):e251. PubMed ID: 28392202
[No Abstract] [Full Text] [Related]
32. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
Grimaldi-Bensouda L; Guillemot D; Godeau B; Bénichou J; Lebrun-Frenay C; Papeix C; Labauge P; Berquin P; Penfornis A; Benhamou PY; Nicolino M; Simon A; Viallard JF; Costedoat-Chalumeau N; Courcoux MF; Pondarré C; Hilliquin P; Chatelus E; Foltz V; Guillaume S; Rossignol M; Abenhaim L;
J Intern Med; 2014 Apr; 275(4):398-408. PubMed ID: 24206418
[TBL] [Abstract][Full Text] [Related]
33. Quadrivalent HPV vaccination reactions--more hype than harm.
Douglas RJ
Aust Fam Physician; 2009 Mar; 38(3):139-42. PubMed ID: 19283255
[TBL] [Abstract][Full Text] [Related]
34. Gardasil: Introducing the new human papillomavirus vaccine.
McLemore MR
Clin J Oncol Nurs; 2006 Oct; 10(5):559-60. PubMed ID: 17063609
[TBL] [Abstract][Full Text] [Related]
35. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism.
Scheller NM; Pasternak B; Svanström H; Hviid A
JAMA; 2014 Jul; 312(2):187-8. PubMed ID: 25005658
[No Abstract] [Full Text] [Related]
36. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
38. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance.
Gold MS; McIntyre P
Sex Health; 2010 Sep; 7(3):320-4. PubMed ID: 20719221
[TBL] [Abstract][Full Text] [Related]
40. Acceptance and compliance with postpartum human papillomavirus vaccination.
Wright JD; Govindappagari S; Pawar N; Cleary K; Burke WM; Devine PC; Lu YS; Tsai WY; Lewin SN; Herzog TJ
Obstet Gynecol; 2012 Oct; 120(4):771-82. PubMed ID: 22996094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
